Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIDME: Macugen for Ischaemic Diabetic Macular Oedema
NCT01175070Phase 4Completed
- Sponsor
- University of Oxford
- Start
- Jan 2011
- Primary completion
- Mar 2013
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegaptanib sodium in diabetic macular edema (DME), sponsored by University of Oxford. Primary endpoint: Change in size of Foveal Avascular Zone at 30 weeks. Started Jan 2011; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01175070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01175070.